Clinical Advances in Weekly GLP-1 Agonists in T2DM

Achieving glycemic control is the most important factor for halting disease progression and limiting morbidity and mortality related to type 2 diabetes mellitus (T2DM). Despite availability of effective therapies, most patients do not achieve guideline-recommended glycated hemoglobin (HbA1c) targets. Multiple reasons are linked to this limited success, including clinical inertia, side effects, and patient treatment preferences. New classes of pharmacologic agents are being developed which can overcome many of these barriers while effectively attaining and maintaining glycemic control in T2DM.

Starting and Staying on Once-Weekly Therapies for T2DM
Join an international panel of experts as they discuss strategies and therapies designed to meet unmet needs in T2DM.
January 26, 2016
Weekly Therapies in Type 2 Diabetes Mellitus: Who Is the Ideal Patient Candidate?
This roundtable discusses clinical inertia and patient nonadherence and also delves into the specifics of treatment intensification.
October 30, 2015

Steering Committee Chair

Michael A. Nauck, MD, PhD
Professor of Internal Medicine;
Head, Specialist Centre for
Diabetes and Metabolic
Diseases, Diabetes Centre,
Bad Lauterberg, Germany

Steering Committee Members

Melanie J. Davies, MD, FRCP
Professor of Diabetes Medicine,
Diabetes Research Unit,
University of Leicester;
Honorary Consultant Physician,
University Hospitals of
Leicester NHS Trust,
Leicester, United Kingdom
Kamlesh Khunti, MBChB, PhD, MD
Professor of Primary Care, Diabetes and Vascular Medicine, Department of Health Science, University of Leicester, Leicester, United Kingdom
Sten Madsbad, DMSc
Professor; Chief Physician,
Department of Endocrinology,
Hvidovre Hospital,
University of Copenhagen,
Hvidovre, Denmark

Luc Martinez, MD
Associate Professor of Family Medicine, University Pierre et Marie Curie; Vice President, French Society of General Medicine, Paris, France
Tina Vilsbøll, MD, DMSc
Head of Diabetes Research, Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark

Disclaimer: This Clinical Advances is intended for an audience of healthcare professionals located outside the United States.

Supported by an independent educational
sponsorship from

Downloadable Slide Kits

Clinical Advances in Weekly GLP-1 Agonists in T2DM
A slide kit emphasizing the importance of an individualized approach to glycemic control in people with T2DM and the role of weekly GLP-1 agonists in patient management.

Clinical Articles

Steering Committee

Michael A. Nauck, MD, PhD

Michael A. Nauck, MD, PhD, has disclosed the following relevant financial relationships.
Served as an advisor or consultant for: Amylin Pharmaceuticals, Inc.; AstraZeneca Pharmaceuticals LP; Berlin-Chemie AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Diartis Pharmaceuticals; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; GlaxoSmithKline; Intarcia Therapeutics, Inc.; Janssen Global Services LLC; Lilly Deutschland GmbH; MannKind Corporation; Menarini Group; Merck Sharp & Dohme Corp.; Merck Sharp & Dohme GmbH; Novartis Pharmaceuticals Corporation; Novo Nordisk; Sanofi; Takeda Pharmaceuticals North America, Inc.; Versartis, Inc.; Wyeth Pharmaceuticals Inc.
Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Berlin-Chemie AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; GlaxoSmithKline; Lilly Deutschland GmbH; Menarini Group; Merck Sharp & Dohme GmbH; MetaCure Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Roche; Tolerx, Inc.

Melanie J. Davies, MD, FRCP

Melanie J. Davies, MD, FRCP, has disclosed the following relevant financial relationships.
Served as an advisor or consultant for: Boehringer Ingelheim Pharmaceuticals, Inc.; Lilly Deutschland GmbH; Merck Sharp & Dohme Corp.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Roche; Sanofi
Served as a speaker or a member of a speakers bureau for: Boehringer Ingelheim Pharmaceuticals, Inc.; Lilly Deutschland GmbH; Merck Sharp & Dohme Corp.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Roche; Sanofi
Received grants for clinical research from: GlaxoSmithKline; Lilly Deutschland GmbH; Merck Sharp & Dohme Corp.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Pfizer Inc.; Sanofi

Kamlesh Khunti, MBChB, PhD, MD

Kamlesh Khunti, MBChB, PhD, MD, has disclosed the following relevant financial relationships.
Served as an advisor or consultant for: Bristol-Myers Squibb Company; Eli Lilly and Company; Merck Sharp & Dohme Corp.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Sanofi
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; Merck Sharp & Dohme Corp.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Sanofi
Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; Merck Sharp & Dohme Corp.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Roche; Sanofi

Sten Madsbad, DMSc

Sten Madsbad, DMSc, has disclosed the following relevant financial relationships.
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Intarcia Therapeutics, Inc.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Lilly; Merck Sharp & Dohme Corp.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Sanofi
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; Merck Sharp & Dohme Corp.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Sanofi
Received grants for clinical research from: Novo Nordisk

Luc Martinez, MD

Luc Martinez, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen Inc.; AstraZeneca Pharmaceuticals LP; GlaxoSmithKline; Ipsen; Mayoly Spindler; Novo Nordisk; Pfizer Inc.; SERVIER

Tina Vilsbøll, MD, DMSc

Tina Vilsbøll, MD, DMSc, has disclosed the following relevant financial relationships.
Served as an advisor or consultant for: Bristol-Myers Squibb Company; Merck Sharp & Dohme Corp.; Novo Nordisk; Takeda Pharmaceuticals North America, Inc.
Served as a speaker or a member of a speakers bureau for: Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Lilly Deutschland GmbH; Merck Sharp & Dohme Corp.; Novo Nordisk; Takeda Pharmaceuticals North America, Inc.
Received grants for clinical research from: Novo Nordisk

	Multiple weekly GLP-1 RAs are now available for hyperglycemia treatment. Which is the most common reason that you elect to use a particular agent?
		Ease of administration
		Gastrointestinal tolerability
		Effects on body weight
		Robustness of glycemic control
		Use in patients with renal dysfunction